WO2022140670A3 - Anti-activin antibodies and methods of using the same - Google Patents

Anti-activin antibodies and methods of using the same Download PDF

Info

Publication number
WO2022140670A3
WO2022140670A3 PCT/US2021/065079 US2021065079W WO2022140670A3 WO 2022140670 A3 WO2022140670 A3 WO 2022140670A3 US 2021065079 W US2021065079 W US 2021065079W WO 2022140670 A3 WO2022140670 A3 WO 2022140670A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
same
antibodies
disease
diseases
Prior art date
Application number
PCT/US2021/065079
Other languages
French (fr)
Other versions
WO2022140670A2 (en
Inventor
Sam Cooper
Christopher HARVEY
Arif JETHA
Max LONDON
Allison NIXON
Elizabeth KOCH
Mike BRISKIN
Original Assignee
Phenomic Ai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomic Ai filed Critical Phenomic Ai
Publication of WO2022140670A2 publication Critical patent/WO2022140670A2/en
Publication of WO2022140670A3 publication Critical patent/WO2022140670A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to anti-activin antibodies, compositions comrpsing the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of a disease or disorder, such as, e.g., cancer, bone disease, cachexia, fibrotic disease, immune disorders, muscle atrophy, neurological diseases, renal diseases, reproductive diseases, and sarcopenia.
PCT/US2021/065079 2020-12-23 2021-12-23 Anti-activin antibodies and methods of using the same WO2022140670A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063129947P 2020-12-23 2020-12-23
US63/129,947 2020-12-23

Publications (2)

Publication Number Publication Date
WO2022140670A2 WO2022140670A2 (en) 2022-06-30
WO2022140670A3 true WO2022140670A3 (en) 2022-09-29

Family

ID=82160184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/065079 WO2022140670A2 (en) 2020-12-23 2021-12-23 Anti-activin antibodies and methods of using the same

Country Status (1)

Country Link
WO (1) WO2022140670A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240409627A1 (en) * 2021-10-18 2024-12-12 The Uab Research Foundation Inhibin antibodies and cancer treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090407A1 (en) * 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
WO2007084344A2 (en) * 2006-01-13 2007-07-26 Novartis Ag Compositions and methods of use for antibodies of dickkopf-1 and/or -4
US20150086556A1 (en) * 2006-09-08 2015-03-26 Amgen Inc. Anti-Activin A Antibodies and Uses Thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
US20170121409A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3 and their uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090407A1 (en) * 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
WO2007084344A2 (en) * 2006-01-13 2007-07-26 Novartis Ag Compositions and methods of use for antibodies of dickkopf-1 and/or -4
US20150086556A1 (en) * 2006-09-08 2015-03-26 Amgen Inc. Anti-Activin A Antibodies and Uses Thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
US20170121409A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3 and their uses

Also Published As

Publication number Publication date
WO2022140670A2 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2018176079A8 (en) Berberine alkaloids in the prevention and/or treatment of intestinal disease
MX2021008094A (en) Methods and compositions for treating cancer.
MX2023002901A (en) Antibodies that bind to il1rap and uses thereof.
EP4365300A3 (en) Treatment/prevention of disease by linc complex inhibition
WO2022140670A3 (en) Anti-activin antibodies and methods of using the same
AU2020211697B2 (en) Thiazolopyridine derivatives as adenosine receptor antagonists
WO2006058869A3 (en) Substituted pteridines for treating inflammatory diseases
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2020190890A8 (en) Nicorandil derivatives
WO2006058867A3 (en) Substituted pteridines for the treatment of inflammatory diseases
CA3154083A1 (en) Methods of promoting scfa production by gut microbiota
TW200628473A (en) Novel heterocycles
MX2021010766A (en) Tsg-6 antibodies and uses therefor.
WO2006056607A8 (en) Substituted pteridines for treating inflammatory diseases
WO2008125902A3 (en) Peripheral and neural inflammatory crosstalk
MX2024011291A (en) Compounds and methods for treating disease
MX2023000499A (en) Inflammatory disease treatment using anti-tissue factor antibodies.
EP4052694A4 (en) COMPOSITION OF EYE DROPS FOR THE PREVENTION OR TREATMENT OF EYE DISEASE
AU2024216821A1 (en) Rifabutin analogs for the treatment of bacterial diseases
WO2024023267A3 (en) Nucleic acid compounds
EP4392053A4 (en) Compositions and methods for treatment of bone-related disease or disorder
EP4304457A4 (en) Treatment of parkinson's disease
AU2024207021A1 (en) Combination therapies comprising anti-cthrc1 antibodies and methods of using the same
GB202016525D0 (en) Formula for 1)strengthening the immune system, 2)healing additional diseases, including coronavirus-covid19 3)improving additional systems of the body

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21912231

Country of ref document: EP

Kind code of ref document: A2